CONGRESS FOR VOTERS

Gregory Murphy (R-NC)

Protecting Patient Access to Cancer and Complex Therapies Act

H.R. 4299 · House bill Health

A Republican bill with 17 Democratic cosponsors · See all 58 cosponsors

Last activity — Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

In committee

Introduced and handed to a committee in the chamber it started in.

The committee holds it, and most bills are never heard from again. A hearing or a committee vote would be news; silence is the usual outcome, and it kills the bill without anyone voting against it.

Its path through Congress

  1. Introduced
  2. In Committee

What this bill would do

  • This bill is titled the Protecting Patient Access to Cancer and Complex Therapies Act.
    • It amends title XVIII of the Social Security Act.
    • The legislation requires manufacturers to provide a rebate for selected drugs and biological products that are subject to maximum fair price negotiation.
    • It outlines the specific calculations for these manufacturer rebates and beneficiary coinsurance amounts.
    • The bill directs rebate deposits into the Federal Supplementary Medical Insurance Trust Fund.
    • It also establishes penalties for failing to comply with the rebate requirements.

Yes· 3 of 13

  • Scored +7

    Would people over 65 be better off under this?

    Directly reduces out-of-pocket drug costs for Medicare beneficiaries, who are predominantly seniors.

  • Scored +7

    Would retired people be better off under this?

    Lowers medical costs for retirees on Medicare Part B.

  • Scored +6

    Would households on low incomes be better off under this?

    Reduces the financial burden of expensive cancer and complex therapies.

The opposite

  • Scored -4

    Would business owners be better off under this?

    Increases financial burden on drug manufacturers through mandatory rebates.